According to Chr. Hansen, Wisconsin-headquartered UAS produces six trademarked probiotic strains within a range of applications, including digestive disorders, immune stimulation, infant probiotics, weight management, and other areas. Chr. Hansen will acquire 100% of the firm from the private equity fund Lakeview Equity Partners, the company’s management team and other shareholders. In a statement, Chr. Hansen claimed that the addition of UAS’s operations will significantly strengthen its Human Health business and its global microbial platform, as it will allow the company to offer a broader range of products to its current customers, while the deal will also provide access to new customers. Closing of the transaction is the subject to the regulatory approval of the US authorities. Mauricio Graber, CEO of Chr. Hansen, said: “We are excited about the acquisition of UAS Labs and look forward to welcoming all its talented people, to join forces in our shared purpose – to develop and expand the global probiotics market, and we look forward to building upon the strengths of both companies. “The two UAS Labs production facilities in the United States will increase our flexibility and capacity to produce, and also create a better balance in our geographical footprint. We believe that the UAS Labs acquisition will accelerate our efforts to grow our Health & Nutrition business globally, especially in the Asian markets.” Kevin Mehring, CEO of UAS Labs, said: “Over the past seven years I have been honoured to lead the team at UAS Labs with our science-backed probiotic solutions. “We have grown and matured in our strain to solution manufacturing capabilities and commitment to clinical research. I could not be more proud of all the dedicated individuals that have worked tirelessly to get us to this point. We are very excited to join Chr. Hansen, and by our shared vision and future.”